These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24889878)

  • 1. Protocol in managing oral surgical patients taking dabigatran.
    Breik O; Cheng A; Sambrook P; Goss A
    Aust Dent J; 2014 Sep; 59(3):296-301; quiz 401. PubMed ID: 24889878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of Dabigatran, a direct thrombin inhibitor, for oral surgery practice.
    Davis C; Robertson C; Shivakumar S; Lee M
    J Can Dent Assoc; 2013; 79():d74. PubMed ID: 23920075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Warfarin versus dabigatran: comparing the old with the new.
    Abraham ME; Marcy TR
    Consult Pharm; 2012 Feb; 27(2):121-4. PubMed ID: 22330953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.
    Berger R; Salhanick SD; Chase M; Ganetsky M
    Ann Emerg Med; 2013 Apr; 61(4):475-9. PubMed ID: 23522810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombin inhibitors: surgical considerations and pharmacology.
    Breik O; Tadros R; Devitt P
    ANZ J Surg; 2013 Apr; 83(4):215-21. PubMed ID: 23384088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Waiting for the new oral anticoagulants: questions and answers about dabigatran].
    Verdecchia P; Agnelli G
    G Ital Cardiol (Rome); 2013 Jan; 14(1):35-45. PubMed ID: 23258203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabigatran: will it change clinical practice?
    Wartak SA; Bartholomew JR
    Cleve Clin J Med; 2011 Oct; 78(10):657-64. PubMed ID: 21968472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
    Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.
    Atay JK; Fanikos J; Barnes GD; Ehle M; Coatney J; Piazza G; Froehlich JB; Goldhaber SZ
    Am J Cardiol; 2013 Aug; 112(3):387-9. PubMed ID: 23647794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Direct oral thrombin inhibitor, "dabigatran"].
    Yasaka M
    Nihon Rinsho; 2013 Jan; 71(1):113-8. PubMed ID: 23631181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.
    Ganetsky M; Babu KM; Salhanick SD; Brown RS; Boyer EW
    J Med Toxicol; 2011 Dec; 7(4):281-7. PubMed ID: 21887485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
    Eikelboom JW; Connolly SJ; Hart RG; Wallentin L; Reilly P; Oldgren J; Yang S; Yusuf S
    J Am Coll Cardiol; 2013 Sep; 62(10):900-8. PubMed ID: 23770182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
    Hohnloser SH; Oldgren J; Yang S; Wallentin L; Ezekowitz M; Reilly P; Eikelboom J; Brueckmann M; Yusuf S; Connolly SJ
    Circulation; 2012 Feb; 125(5):669-76. PubMed ID: 22215856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dental implications of new oral anticoagulants for atrial fibrillation.
    Curtin C; Hayes JM; Hayes J
    Dent Update; 2014; 41(6):526-8, 530-1. PubMed ID: 25195485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
    Ali A; Bailey C; Abdelhafiz AH
    Age Ageing; 2012 Sep; 41(5):681-4. PubMed ID: 22378612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study.
    Monz BU; Connolly SJ; Korhonen M; Noack H; Pooley J
    Int J Cardiol; 2013 Oct; 168(3):2540-7. PubMed ID: 23664436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of venous thromboembolism with dabigatran.
    Schulman S
    Curr Opin Pulm Med; 2012 Sep; 18(5):410-5. PubMed ID: 22617811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemostasis. Part 2: Medications that affect haemostasis.
    McCormick NJ; Moore UJ; Meechan JG; Norouzi M
    Dent Update; 2014 Jun; 41(5):395-6, 399-402, 405. PubMed ID: 25073220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.